95 results
8-K
EX-99.1
NVTAQ
Invitae Corp
7 Sep 21
Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research
8:01am
part of its strategy to be the industry leader across the genetic testing, software and health information technology spaces,” said Sean George, Ph.D … . Patient control is the big differentiator at Ciitizen and at Invitae; and we believe combining forces is the right strategy for our business going
8-K
NVTAQ
Invitae Corp
11 Sep 18
Departure of Directors or Certain Officers
12:00am
of Global Sales Development from February 2008 to January 2013 and Vice President of Marketing Strategy & Operations from February 2007 to January 2008 … insurance. From 1999 to 2003, Ms. Nayak served as Vice President, Strategy & Operations of Charles Schwab Corporation, an investment and brokerage firm
8-K
NVTAQ
Invitae Corp
1 Apr 20
Regulation FD Disclosure
4:39pm
, strategy, short- and long-term business operations and objectives, and financial requirements. Forward-looking statements are subject to risks … strategy to create a profitable long-term business; the Company’s ability to integrate and scale acquired businesses and realize the intended benefits
8-K
NVTAQ
Invitae Corp
1 Apr 20
Invitae Announces Proposed Public Offering of Common Stock
4:34pm
of operations, strategy, short- and long-term business operations and objectives, and financial requirements. Forward-looking statements are subject to risks … and to execute its strategy to create a profitable long-term business; the Company’s ability to integrate and scale acquired businesses and realize the intended
8-K
EX-99.1
NVTAQ
Invitae Corp
13 Nov 19
Invitae to Acquire Clear Genetics
4:09pm
and the impact thereof; the company’s business strategy, and its beliefs regarding the ways in which the proposed acquisition will contribute to that strategy
8-K
EX-99.1
wzh z750bgy0dmqz
17 Jun 19
Invitae to Acquire Singular Bio to Help Increase Access to Genetic Screening in Early Pregnancy
8:41am
8-K
EX-99.3
7nqq1r
18 Jul 22
Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow
9:28pm
8-K
EX-99.1
rmc96gtg
20 Dec 22
Other Events
9:00am
8-K
EX-99.1
9xj9ma3 7lgw3mx5a5
12 Jun 18
Regulation FD Disclosure
7:31am
8-K
sp59zn8yv
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.2
ilrog xms
7 Sep 21
Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research
8:01am
8-K
EX-99.1
jguky
11 Jan 22
Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million
4:20pm
8-K
EX-99.2
kpav4c 2160e0
10 Mar 20
Invitae to Acquire YouScript and Genelex to Make it Easier to Use Pharmacogenetic Information at the Point of Care
4:33pm
8-K
EX-99.2
14y2qlsj
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K
EX-99.1
p22u9jjrc1h2r2hf xq
6 Aug 19
Invitae Reports $53.5 Million in Quarterly Revenue Driven by More Than 111,000 Samples in Quarterly Volume
4:17pm
8-K
EX-99.1
jeosdsbqwqa5n
11 Jul 19
Entry into a Material Definitive Agreement
4:40pm
8-K
EX-99.1
n7vv5p
10 Mar 20
Invitae to Acquire YouScript and Genelex to Make it Easier to Use Pharmacogenetic Information at the Point of Care
4:33pm
8-K
EX-99.1
xs8l 9vnmspns
7 May 19
Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year
4:15pm
8-K
EX-99.1
gzn7s5ew03 s3
4 Aug 20
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
4:13pm
8-K
EX-99.2
29a42
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm